Home
Archives
Jerusalem Center Homepage
View the current issue
Jerusalem Center Videos
Additional Resources
Top Commentators:
- Elliott Abrams
- Fouad Ajami
- Shlomo Avineri
- Benny Avni
- Alan Dershowitz
- Jackson Diehl
- Dore Gold
- Daniel Gordis
- Tom Gross
- Jonathan Halevy
- David Ignatius
- Pinchas Inbari
- Jeff Jacoby
- Efraim Karsh
- Mordechai Kedar
- Charles Krauthammer
- Emily Landau
- David Makovsky
- Aaron David Miller
- Benny Morris
- Jacques Neriah
- Marty Peretz
- Melanie Phillips
- Daniel Pipes
- Harold Rhode
- Gary Rosenblatt
- Jennifer Rubin
- David Schenkar
- Shimon Shapira
- Jonathan Spyer
- Gerald Steinberg
- Bret Stephens
- Amir Taheri
- Josh Teitelbaum
- Khaled Abu Toameh
- Jonathan Tobin
- Michael Totten
- Michael Young
- Mort Zuckerman
Think Tanks:
- American Enterprise Institute
- Brookings Institution
- Center for Security Policy
- Council on Foreign Relations
- Heritage Foundation
- Hudson Institute
- Institute for Contemporary Affairs
- Institute for Counter-Terrorism
- Institute for Global Jewish Affairs
- Institute for National Security Studies
- Institute for Science and Intl. Security
- Intelligence and Terrorism Information Center
- Investigative Project
- Jerusalem Center for Public Affairs
- RAND Corporation
- Saban Center for Middle East Policy
- Shalem Center
- Washington Institute for Near East Policy
Media:
- CAMERA
- Daily Alert
- Jewish Political Studies Review
- MEMRI
- NGO Monitor
- Palestinian Media Watch
- The Israel Project
- YouTube
Government:
Back
(Jewish Chronicle-UK) Marina Yannakoudakis - The politicization of a technical agreement with Israel that will facilitate the import of high-quality and affordable medicines into Europe has already caused delays in the provision of life-saving drugs to European patients at lower prices. When the "Protocol on Conformity Assessment and Acceptance of Industrial Products" is voted on by all members of the European Parliament this week, it will have taken over two years of negotiations to finalize an already established joint commitment with Israel. Israel's Teva Pharmaceuticals makes Copaxone, the world's top selling treatment for multiple sclerosis. The company has also produced a generic version of Lipitor, the popular blood pressure medication and the world's best-selling drug. Teva also produces a generic version of Actos, which is used to improve blood sugar control in adults with type 2 diabetes. According to industry estimates, Europeans save nearly 25 billion euros annually by using generics. The writer is Conservative MEP for London in the European Parliament. 2012-10-24 00:00:00Full Article
EU Needs Israeli Medicines
(Jewish Chronicle-UK) Marina Yannakoudakis - The politicization of a technical agreement with Israel that will facilitate the import of high-quality and affordable medicines into Europe has already caused delays in the provision of life-saving drugs to European patients at lower prices. When the "Protocol on Conformity Assessment and Acceptance of Industrial Products" is voted on by all members of the European Parliament this week, it will have taken over two years of negotiations to finalize an already established joint commitment with Israel. Israel's Teva Pharmaceuticals makes Copaxone, the world's top selling treatment for multiple sclerosis. The company has also produced a generic version of Lipitor, the popular blood pressure medication and the world's best-selling drug. Teva also produces a generic version of Actos, which is used to improve blood sugar control in adults with type 2 diabetes. According to industry estimates, Europeans save nearly 25 billion euros annually by using generics. The writer is Conservative MEP for London in the European Parliament. 2012-10-24 00:00:00Full Article
Search Daily Alert
|
Search:
|